These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32002175)

  • 1. Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis.
    Lassenius MI; Toppila I; Pöntynen N; Kasslin L; Kaunisto J; Kilpeläinen M; Laitinen T
    Eur Clin Respir J; 2020; 7(1):1702618. PubMed ID: 32002175
    [No Abstract]   [Full Text] [Related]  

  • 2. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
    Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
    BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study.
    Cano-Jiménez E; Romero Ortiz AD; Villar A; Rodríguez-Nieto MJ; Ramon A; Armengol S
    Respir Res; 2022 Sep; 23(1):235. PubMed ID: 36071483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.
    Veit T; Barnikel M; Crispin A; Kneidinger N; Ceelen F; Arnold P; Munker D; Schmitzer M; Barton J; Schiopu S; Schiller HB; Frankenberger M; Milger K; Behr J; Neurohr C; Leuschner G
    Respir Res; 2020 Oct; 21(1):270. PubMed ID: 33076914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
    Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
    Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study.
    Adams CJ; Shapera S; Ryerson CJ; Assayag D; Johannson KA; Fell CD; Morisset J; Manganas H; Kolb M; Hambly N; Cox G; Khalil N; Marcoux V; Wilcox PG; To T; Sadatsafavi M; Halayko AJ; Gershon A; Garlick K; Fisher JH
    Respir Med; 2022 Jan; 191():106722. PubMed ID: 34959146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization.
    Singer D; Chastek B; Sargent A; Johnson JC; Shetty S; Conoscenti C; Bernstein EJ
    BMC Pulm Med; 2023 Sep; 23(1):337. PubMed ID: 37689630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study.
    Wijsenbeek MS; Bendstrup E; Valenzuela C; Henry MT; Moor CC; Jouneau S; Fois AG; Moran-Mendoza O; Anees S; Mirt M; Bengus M; Gilberg F; Kirchgaessler KU; Vancheri C
    Adv Ther; 2021 Jul; 38(7):4040-4056. PubMed ID: 34117601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study).
    Rodríguez-Nieto MJ; Cano-Jiménez E; Romero Ortiz AD; Villar A; Morros M; Ramon A; Armengol S
    Pharmacoeconomics; 2023 Aug; 41(8):999-1010. PubMed ID: 37249823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization.
    Yu YF; Macaulay DS; Reichmann WM; Wu EQ; Nathan SD
    Respir Med; 2015 Dec; 109(12):1582-8. PubMed ID: 26607877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome.
    Jacob J; Aksman L; Mogulkoc N; Procter AJ; Gholipour B; Cross G; Barnett J; Brereton CJ; Jones MG; van Moorsel CH; van Es W; van Beek F; Veltkamp M; Desai SR; Judge E; Burd T; Kokosi M; Savas R; Bayraktaroglu S; Altmann A; Wells AU
    Thorax; 2020 Aug; 75(8):648-654. PubMed ID: 32345689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.
    Behr J; Prasse A; Wirtz H; Koschel D; Pittrow D; Held M; Klotsche J; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Kahn N; Welte T; Neurohr C; Schwaiblmair M; Bahmer T; Oqueka T; Frankenberger M; Kreuter M
    Eur Respir J; 2020 Aug; 56(2):. PubMed ID: 32381492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality.
    Hyldgaard C; Møller J; Bendstrup E
    Eur Clin Respir J; 2020 Aug; 7(1):1807682. PubMed ID: 32944203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients.
    Kishaba T; Nagano H; Nei Y; Yamashiro S
    J Thorac Dis; 2016 Dec; 8(12):3596-3604. PubMed ID: 28149554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons.
    Nathan SD; Wanger J; Zibrak JD; Wencel ML; Burg C; Stauffer JL
    Expert Rev Respir Med; 2021 Feb; 15(2):175-181. PubMed ID: 32985286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
    Zappala CJ; Latsi PI; Nicholson AG; Colby TV; Cramer D; Renzoni EA; Hansell DM; du Bois RM; Wells AU
    Eur Respir J; 2010 Apr; 35(4):830-6. PubMed ID: 19840957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.